Abstract
Cancer Targeting Gene-Viro-Therapy (CTGVT) and Gene Armed Oncolytic Virus Therapy (GAOVT) both are identical by inserting an antitumor gene into an oncolytic virus. This approach has gradually become a hot topic in cancer therapy, because that CTGVT (GAOVT) has much higher antitumor than that of either gene therapy alone or oncolytic virotherapy alone. We proposed the CTGVT strategy in 1999-2001, insisted it as a long term systematic approach to be examined over 10 years and have published 68 SCI papers some in good Journals. The CD gene armed oncolytic adenovirus therapy (GAOVT) for cancer treatment with potent antitumor effect was also named in our laboratory in 2003. Several modifications to CTGVT will be carried out by our group and will be introduced briefly in this paper. Most importantly, the modifications of CTGVT usually resulted in complete eradication of xenograft tumors in nude mice. In future best antitumor drugs may emerge from the modified CTGVT strategy and not from either gene therapy or virotherapy alone.
Keywords: Cancer therapy, Cancer targeting, Gene Viro-Therapy, Trend of gene therapy, Trend of virotherapy, Gene Armed Oncolytic Virus Therapy (GAOVT), oncolytic virotherapy, cancer, xenograft tumors, melanoma
Current Pharmaceutical Biotechnology
Title:Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Volume: 13 Issue: 9
Author(s): Xin -Yuan Liu, Hua -Guang Li, Kang -Jian Zhang and Jin -Fa Gu
Affiliation:
Keywords: Cancer therapy, Cancer targeting, Gene Viro-Therapy, Trend of gene therapy, Trend of virotherapy, Gene Armed Oncolytic Virus Therapy (GAOVT), oncolytic virotherapy, cancer, xenograft tumors, melanoma
Abstract: Cancer Targeting Gene-Viro-Therapy (CTGVT) and Gene Armed Oncolytic Virus Therapy (GAOVT) both are identical by inserting an antitumor gene into an oncolytic virus. This approach has gradually become a hot topic in cancer therapy, because that CTGVT (GAOVT) has much higher antitumor than that of either gene therapy alone or oncolytic virotherapy alone. We proposed the CTGVT strategy in 1999-2001, insisted it as a long term systematic approach to be examined over 10 years and have published 68 SCI papers some in good Journals. The CD gene armed oncolytic adenovirus therapy (GAOVT) for cancer treatment with potent antitumor effect was also named in our laboratory in 2003. Several modifications to CTGVT will be carried out by our group and will be introduced briefly in this paper. Most importantly, the modifications of CTGVT usually resulted in complete eradication of xenograft tumors in nude mice. In future best antitumor drugs may emerge from the modified CTGVT strategy and not from either gene therapy or virotherapy alone.
Export Options
About this article
Cite this article as:
Liu Xin -Yuan, Li Hua -Guang, Zhang Kang -Jian and Gu Jin -Fa, Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958869
DOI https://dx.doi.org/10.2174/138920112800958869 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Atomic Force Microscopy: The Characterisation of Amyloid Protein Structure in Pathology
Current Topics in Medicinal Chemistry Novel Aspects of Natural and Modified Vinca Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772)
Current Cancer Drug Targets Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Genetic Idiotypic and Tumor Cell-Based Vaccine Strategies for Indolent Non Hodgkins Lymphoma
Current Gene Therapy HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging